These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 15615494

  • 1. The OPG/RANKL/RANK system in metabolic bone diseases.
    Hofbauer LC, Kühne CA, Viereck V.
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):268-75. PubMed ID: 15615494
    [Abstract] [Full Text] [Related]

  • 2. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.
    Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC.
    Calcif Tissue Int; 2004 Jan; 74(1):103-6. PubMed ID: 14523602
    [Abstract] [Full Text] [Related]

  • 3. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS, Rettmer E, Eriksen EF, Hegedüs L, Beck-Nielsen H, Abrahamsen B.
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [Abstract] [Full Text] [Related]

  • 4. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 5. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
    Saunders MM, Taylor AF, Du C, Zhou Z, Pellegrini VD, Donahue HJ.
    J Biomech; 2006 Aug 25; 39(8):1419-27. PubMed ID: 15953606
    [Abstract] [Full Text] [Related]

  • 6. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
    Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S.
    Biochem Biophys Res Commun; 2001 Jan 12; 280(1):334-9. PubMed ID: 11162519
    [Abstract] [Full Text] [Related]

  • 7. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.
    Cytokine Growth Factor Rev; 2004 Dec 12; 15(6):457-75. PubMed ID: 15561602
    [Abstract] [Full Text] [Related]

  • 8. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.
    Rev Invest Clin; 2001 Dec 12; 53(4):362-9. PubMed ID: 11599485
    [Abstract] [Full Text] [Related]

  • 9. Heritable disorders of the RANKL/OPG/RANK signaling pathway.
    Whyte MP, Mumm S.
    J Musculoskelet Neuronal Interact; 2004 Sep 12; 4(3):254-67. PubMed ID: 15615493
    [Abstract] [Full Text] [Related]

  • 10. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan 12; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 11. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
    Humphrey EL, Williams JH, Davie MW, Marshall MJ.
    Bone; 2006 May 12; 38(5):652-61. PubMed ID: 16298558
    [Abstract] [Full Text] [Related]

  • 12. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS.
    J Endocrinol; 2005 Jun 12; 185(3):401-13. PubMed ID: 15930166
    [Abstract] [Full Text] [Related]

  • 13. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
    Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ.
    J Musculoskelet Neuronal Interact; 2004 Sep 01; 4(3):276-84. PubMed ID: 15615495
    [Abstract] [Full Text] [Related]

  • 17. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Sep 01; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 18. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 01; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Aug 01; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 20. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T, Nakashima T, Hiroshi N, Penninger JM.
    Trends Mol Med; 2006 Jan 01; 12(1):17-25. PubMed ID: 16356770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.